Stem Cells Offer Solution To Kidney Transplant Patients
Published on 06 October 2011. | Written by Terry Hixon
Stem Cells Offer Solution To Kidney Transplant Patients
Kidney failure occurs frequently in the United States and is primarily caused by poorly controlled diabetes or high blood pressure. Treatment for kidney failure include both dialysis and organ transplantation. Dialysis is an intensive regime of treatments three times per week designed to clean and filter the blood. The initial cost for organ failure in the first year is around $80,000 and the costs for dialysis terwards are around $70,000 per year.
Kidney transplantation has increased in the United States. According to the National Kidney Foundation, 16,901 procedures were performed in the United States in 2010, compared with 16,634 in 2007.Kidney transplants are commonplace in the USA and while they do improve the quality of life for someone in renal failure, they are no walk in the park either. The procedure carries with it a lifelong regime of drugs that have to be taken to help prevent rejection of the transplanted organ.
Recently, scientists have developed a novel stem cell therapy that is administered right after transplant surgery. This new therapy allows some transplant recipients to avoid taking the immunosuppressant drugs that most have to take. The New England Journal of Medicine reports data on 12 patients that received a kidney from a perfect matching donor. Eight of the twelve patients were given the new stem cell therapy and have been off the medication for at least one year and some as much as three.
The new therapy is a combination of radiation, stem cells and antibodies. The therapy is given post transplantation of the new organ. The new recipient receives radiation to the lymph nodes, spleen and thymus gland as well as administration of the antibodies to weaken the immune system.
Ten days later, the stem cells (hematopoietic progenitor cells) are administered. These cells form blood and immune cells and are infused on an outpatient basis. The stem cells eventually join with the immune system making the donor kidney more compatible with the host body. A few immunosuppressive drugs are given at first, but the patient is quickly taken off of them. The goal was to eliminate the immunosuppressive drugs from the mix and to allow the patient to keep the kidney as well. So far, eight of study patients still have their kidneys and they function well.
The research holds promise for improving more lives down the road. The problem of keeping people on immune-suppressing drugs is very significant. The fact that using stem cells as a way to overcome that is creatively sound science. If you just think about what these patients go through, they have had so much to deal with already. Considering dialysis, waiting for a transplant and getting to resume life without the constant drugs is a step towards a working solution for all transplant patients.
http://amazingnews.org/stem-cells-offer-solution-to-kidney-transplant-patients/562981/
干细胞提供解决方案为肾移植患者
发表于2011年10月06日。 |作者：特里Hixon
干细胞提供解决方案为肾移植患者
肾功能衰竭在美国经常发生，主要是由控制不佳的糖尿病或血压高引起的。肾功能衰竭的治疗包括血液透析和器官移植。透析治疗每周3次，清洁和过滤血液的密集制度。器官功能衰竭在第一年的初始投资成本是80,000元左右，而透析terwards的费用是每年70,000美元左右。
在美国增加了肾移植。据全国肾脏基金会，16901程序在2010年在美国相比2007.Kidney移植16,634，在美国已是家常便饭，虽然他们改善肾功能衰竭的人的生活质量，他们没有步行在公园。该程序带有一个终身政权必须采取的药物，有助于防止移植器官的排斥。
最近，科学家们已经开发出一种新型干细胞治疗，移植手术后的管理。这种新疗法可避免服用免疫抑制药物，大多数采取一些移植受者。新英格兰医学杂志报告数据对12例患者，收到了一个完美匹配捐助者的肾脏。 12位患者中有8个被赋予新的干细胞疗法，并已服药至少一年，有的高达三个多。
这种新的治疗是一个辐射，干细胞和抗体的结合。该疗法的新的器官移植后。新的收件人接收辐射的淋巴结，脾和胸腺以及管理削弱免疫系统的抗体。
十天后，干细胞（造血干细胞）的管理。这些细胞形成血液和免疫细胞，并在门诊的基础上上注入。这些干细胞最终加入使供肾与兼容的宿主体内的免疫系统。在第一，但少数免疫抑制药物给予病人，他们迅速采取关闭。我们的目标是，以消除免疫抑制药物的混合，并让病人保持以及肾脏。到目前为止，8个研究的病人仍然有他们的肾脏和它们的功能以及。
该研究认为在道路改善更多人的生命的承诺。保持免疫抑制药物的人的问题是非常显著的。事实上，利用干细胞的一种方式，克服创造性健全科学。如果你只是认为这些患者经过，他们有这么多已经处理。考虑透析，等待移植手术，恢复生活没有恒定的药物，是对工作的解决方案为所有移植患者的一个步骤。
http://www.dailymail.co.uk/health/article-2046418/Kidney-breakthrough-free-transplant-patients-lifetime-anti-rejection-drugs.html |
发表于 2011-10-8 09:30:13